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Abstract
Introduction: Novel compounds with potential to attenuate or stop the progression of Alzheimer’s disease (AD)
from its presymptomatic stage to dementia are being tested in man. The study design commonly used is the
long-term randomized, placebo-controlled trial (RPCT), meaning that many patients will receive placebo for
18 months or longer. It is ethically problematic to expose presymptomatic AD patients, who by definition are at
risk of developing dementia, to prolonged placebo treatment. As an alternative to long-term RPCTs we propose a
novel clinical study design, termed the placebo group simulation approach (PGSA), using mathematical models to
forecast outcomes of presymptomatic AD patients from their own baseline data. Forecasted outcomes are
compared with outcomes observed on candidate drugs, thus replacing a concomitant placebo group.
Methods: First models were constructed using mild cognitive impairment (MCI) data from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database. One outcome is the Alzheimer Disease Assessment Scale - cognitive
subscale (ADAScog) score after 24 months, predicted in a linear regression model; the other is the trajectory over
36 months of a composite neuropsychological test score (Neuro-Psychological Battery (NP-Batt)), using a mixed
model. Demographics and clinical, biological and neuropsychological baseline values were tested as potential
predictors in both models.
Results: ADAScog scores after 24 months are predicted from gender, obesity, Functional Assessment Questionnaire
(FAQ) and baseline scores of Mini-Mental State Examination, ADAScog and NP-Batt with an R2 of 0.63 and a residual
standard deviation of 0.67, allowing reasonably precise estimates of sample means. The model of the NP-Batt trajectory
has random intercepts and slopes and fixed effects for body mass index, time, apolipoprotein E4, age, FAQ, baseline
scores of ADAScog and NP-Batt, and four interaction terms. Estimates of the residual standard deviation range from 0.3
to 0.5 on a standard normal scale. If novel drug candidates are expected to diminish the negative slope of scores with
time, a change of 0.04 per year could be detected in samples of 400 with a power of about 80%.
Conclusions: First PGSA models derived from ADNI MCI data allow prediction of cognitive endpoints and
trajectories that correspond well with real observed values. Corroboration of these models with data from other
observational studies is ongoing. It is suggested that the PGSA may complement RPCT designs in forthcoming
long-term drug studies with presymptomatic AD individuals.
Introduction
A number of compounds with potential to attenuate the
progression of Alzheimer’s disease (AD) from a pre-
symptomatic stage to dementia - that is, drugs intended
for secondary prevention of dementia due to AD - are
currently undergoing testing in man [1,2]. The study
design routinely applied in advanced stages of clinical
development (late phase 2, phase 3) of central nervous
system active compounds is that of the randomized, pla-
cebo-controlled clinical trial (RPCT), a procedure imply-
ing that a high proportion of patients, up to 50% of the
total sample, will receive inactive drug throughout.
Given that meaningful study of experimental treatment
intended for secondary prevention of dementia due to
AD will take 18 months or more for each individual, it
is problematic, from an ethical standpoint, to expose
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patients with mild cognitive impairment (MCI) and
similar conditions, who by definition run a high risk of
developing dementia, to prolonged exposure to placebo
[3]. In addition, the external validity (representativity) of
long-term RPCTs may be questioned, as many potential
trial participants will decline inclusion in a study that
intentionally exposes them to the risk of prolonged inac-
tive treatment.
Although several groups of investigators have dis-
cussed more focused and/or more time-economical
approaches to testing potential AD course-altering treat-
ments [4-8], including variations of the conventional
parallel-group clinical study design, little or no attention
has been paid to the two fundamental problems of long-
term RPCTs in high-risk individuals: the ethical issue of
extended placebo exposure, and the problem of the
trials’ external validity. Here we propose a novel clinical
strategy - the placebo group simulation approach
(PGSA) - thought to be a viable alternative to long-term
RPCTs and able to overcome a serious ethical and
scientific dilemma of current clinical research in AD
and similar conditions. Making use of anamnestic, biolo-
gical, neuropsychological and other subject data routi-
nely established at study baseline, the PGSA comprises
mathematical modeling and forecasting of typical AD
disease trajectories from its presymptomatic to sympto-
matic stages. Based on such forecasts, the endpoints and
trajectories of patients undergoing experimental treat-
ment intended for secondary prevention of dementia
due to AD can be compared with their own modeled
disease course; that is, with their predicted endpoints
and trajectories had they not been treated. Based on
these comparisons between observed and model-based
outcomes, the efficacy of putative AD course-altering
drugs can be delineated.
The present article describes the development of the
predictive models, based on a large, multidimensional
dataset collected from individuals characterized as MCI
subjects - that is, presymptomatic individuals with a
high risk to develop dementia within a few years. As
will be noted, the PGSA differs from traditional histori-
cal control and observation studies with regard to three
critical aspects. First, this approach uses mathematical
modeling to identify and quantify those measures at
baseline that allow one to forecast cognitive and/or
other clinically relevant outcomes after a predetermined
time period. Second, based on a variety of measures
established at baseline, the PGSA provides a quantified
prediction as to the expected time course of the out-
comes selected by the investigators. Third, the predictive
models of the PGSA are based on large sets of uni-
formly collected longitudinal observational data of prop-
erly defined patient samples. Furthermore, although the
PGSA could be expanded to other areas of medicine
where longitudinal data allowing computation of respec-
tive models are available, the focus of the present paper
is on AD.
Materials and methods
Subjects and procedures
Data used in the preparation of this article were
obtained from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database [9]. The ADNI was launched
in 2003 by the National Institute on Aging, the National
Institute of Biomedical Imaging and Bioengineering, the
Food and Drug Administration, private pharmaceutical
companies and nonprofit organizations. The primary
goal of ADNI has been to test whether serial magnetic
resonance imaging, positron emission tomography, other
biological markers, and the progression of mild cognitive
impairment and early Alzheimer’s disease. Determina-
tion of sensitive and specific markers of very early AD
progression is intended to aid researchers and clinicians
in developing new treatments and monitoring their
effectiveness, as well as to lessen the time and cost of
clinical trials.
The Principal Investigator of this initiative is Michael
W Weiner, MD (VA Medical Center and University of
California - San Francisco, CA, USA). The ADNI is the
result of efforts of many co-investigators from a broad
range of academic institutions and private corporations,
and subjects have been recruited from over 50 sites
across the United States and Canada. The initial goal of
the ADNI was to recruit 800 adults, ages 55 to 90, to
participate in the research - approximately 200 cogni-
tively normal older individuals to be followed for
3 years, 400 people with MCI to be followed for 3 years
and 200 people with early AD to be followed for
2 years. Up-to-date information is available online [9].
For the present analyses, we focus on the MCI subjects
in the ADNI database. Participants were classified as
MCI in the ADNI project when they had a Mini-Mental
State Examination (MMSE) [10] score between 24 and
30, a memory complaint, a memory loss measured by
education-adjusted scores on the Wechsler Memory
Scale - Logical Memory II, a Clinical Dementia Rating
[11] of 0.5, an absence of significant levels of impairment
in other cognitive domains, essentially preserved activities
of daily living, and an absence of dementia [12].
There was a total of 397 subjects with MCI at baseline
(Table 1). These individuals were followed up at 6, 12, 18,
24 and 36 months. Data from 286 subjects with evalua-
tions at baseline and at month 24 were available for an
endpoint-related univariate analysis of outcomes after
2 years, and there were 375 subjects available with baseline
and at least one postbaseline evaluation for a trajectory-
related multivariate model (status October 2009). A total
of 199 of the 397 subjects had undergone lumbar puncture
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at baseline, and 189 of these had at least one postbaseline
cognitive testing. Note that a number of these MCI sub-
jects had functional impairments at baseline (as indicated
by elevated Functional Assessment Questionnaire (FAQ)
scores) and that more than one-half of them took relevant
medication for some time - specifically cholinesterase inhi-
bitors or memantine, or a combination of these drugs.
Baseline data and neuropsychological assessments
On every visit, the following neuropsychological tests were
administered: MMSE, Alzheimer Disease Assessment
Scale - cognitive subscale (ADAScog) [13], Wechsler
Memory Scale - Revised Logical Memory I and II, Audi-
tory Verbal Learning Test, Boston Naming Test, Trail
Making Test A and B, Digit Symbol Test (forward and
backward), Clock Drawing Test and Category Fluency
(animals and vegetables) [14]. For what we term univariate
(endpoint-related) analysis, we used the ADAScog modi-
fied total score - that is, the traditional ADAScog total
score plus Delayed Word Recall and Digit Cancellation
with a maximum score of 85 (Table 1). For what is termed
multivariate (trajectory-related) analysis, we computed a
neuropsychological composite score (Neuro-Psychological
Battery (NP-Batt)) as defined by Cronk and colleagues
[15]. This is the average of nine z scores determined by
standardization with means and standard deviations (SDs)
of the normal controls of the ADNI database. The nine
subtests are: Logical Memory II, Digit Span Forward, Digit
Span Backward, category fluency animals, category fluency
vegetables, Trail Making B, Boston Naming Test, Auditory
Verbal Learning Test, and Digit Symbol Test.
Response variables for our models were ADAScog at
24 months and NP-Batt scores at all follow-up visits.
We used baseline evaluations of these scores, plus
demographics (age, gender, years of education, body
mass index, number of apolipoprotein E4 alleles), the
Hachinski modified score, the total score of the FAQ
[16] and the MMSE score as potential predictors in our
models. The body mass index is divided into three
classes: <25 kg/m2, ≥25 to <30 kg/m2, ≥30 kg/m2. In
supplementary analyses with a smaller subject sample
we also included the ratio of the cerebrospinal fluid
biomarkers b-amyloid1-42 (Ab42) over total tau protein
(T-tau) as a potential predictor.
Statistical analysis
In the univariate analysis we forecast the ADAScog after
24 months from demographic variables, apolipoprotein
E4, body mass index, modified Hachinski score, and base-
line values of FAQ, MMSE, ADAScog and NP-Batt
scores in a linear regression model. Twenty-four months
were chosen because this is a time span in which signifi-
cant cognitive decline may be expected in MCI subjects
and because there were many missing values in the data-
base at later times. As the distribution of ADAScog
scores is heavily skewed to the right, a square-root trans-
formation was applied. Variable selection is based on the
Akaike Information Criterion [17] and, after the main
effects model is found, all pairwise interactions are tested
for inclusion in this model. Simulated control group data
are generated by randomly generating a parameter vector
from the multivariate normal distribution of the esti-
mated parameter vector, by applying this parameter vec-
tor to the covariate values of the individual considered
(that is, forming the linear combination), and by adding
random noise with the variance of the residuals. Power
calculation is based on the assumption that treated indivi-
duals would have a lower ADAScog score at 24 months
(that is, less deterioration) than untreated controls. The
standard power formula for comparison of two means is
applied. Since a randomized treatment is uncorrelated
with other covariates, this formula drops from the more
general procedure for parameters in regression models.
The multivariate model is a mixed model with ran-
dom intercepts and random slopes versus time [18]. It is
computed for the NP-Batt score at all follow-up visits.
We include the same predictors as those in the univari-
ate analysis as well as the interactions of these predic-
tors with time in a starting model, and eliminate effects
in a stepwise manner based on their P values. We then
test whether pairwise interactions of main effects that
Table 1 Demographic and baseline data for the mild
cognitive impairment group
Characteristic Value
(n = 397)
Age (years) 74.2 (7.4)
Women 141 (36%)
Apolipoprotein E4
0 E4 alleles 185 (47%)
1 E4 allele 165 (42%)
2 E4 alleles 47 (12%)
Education (years) 15. 7 (3.0)
Body mass index (kg/m2) 26.1 (4.0)
Hachinski modified (0 to 12) 1 (0 to 4)
FAQ (0 (normal) to 50) 2 (0 to 21)
MMSE (0 to 30 (best)) 27.0 (1.8)
ADAScog, modified (0 (best) to 85) 18.6 (6.3)
NP-Batt (z score) -1.02 (0.66)
Medication 240 (60%)
(n = 199)
b-amyloid1-42 146.9 (48.3 to 298.8)
Total tau protein 85.6 (28.5 to 463.2)
b-amyloid1-42/total tau protein 1.564 (0.233 to 7.61)
Data presented as mean (standard deviation), n (%) or median (minimum to
maximum). ADAScog, Alzheimer Disease Assessment Scale - cognitive
subscale; FAQ, Functional Assessment Questionnaire; MMSE, Mini-Mental State
Examination; NP-Batt, Neuro-Psychological Battery.
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stayed in the model should be included. Time is coded
as the visit number in units of 6 months; that is, the
visit at month 36 has the visit number 6. All slopes on
time are changes per visit. Simulated control group data
are generated in a similar manner as in the univariate
model with additional simulation of individual random
effects. The power is determined by simulation: we
simulated 1,000 treatment datasets (with the covariates
of the ADNI MCI) with slope -0.74 and compared each
of them with the given control group, which had a slope
of -0.94.
For both types of models we display effects in profile
plots. We compare the simulated response variables
with their observed counterparts. The validity of the
model was checked by fivefold cross-validation; that is,
the dataset was randomly split into five equally sized
subsets, responses of each subset were predicted by a
model estimated from the union of the other subsets
and the overall prediction error was determined by
comparing all predictions with the actual observed
responses. As co-linearity might be a concern, we com-
puted the variance inflation factor of each quantitative
predictor: they were all below 1.70 (that is, a fairly low
value).
Results
Preliminary analysis with the number of apolipoprotein
E4 alleles placed into three categories (0, 1, 2) showed
that two alleles approximately duplicated the effect of
one allele. We therefore put the number of E4 alleles as
a numerical predictor in our models.
Univariate analysis
Starting with all potential predictors of the square-root-
transformed ADAScog total at 24 months (see Baseline
data and neuropsychological assessments), years of edu-
cation, age, Hachinski score and the number of E4
alleles were eliminated in backward stepping with the
Akaike Information Criterion. Subsequent testing for
single pairwise interactions yielded four significant
results, but only one - the interaction of FAQ with NP-
Batt - remained in the model after another Akaike
Information Criterion-based elimination. The ADAScog
total at baseline seems to be the strongest predictor in
this model (Table 2).
Fivefold cross-validation with 20% of the responses
predicted in each run achieved a mean prediction error
of 0.671, very close to the residual SD of 0.669. This
confirms the stability of the model.
The interaction of FAQ with NP-Batt (both at base-
line) is displayed as a profile plot with FAQ fixed at its
quartiles (Figure 1). At low values of the NP-Batt score,
the ADAScog total is not dependent on the FAQ; but at
normal values of the NP-Batt, the ADAScog total score
is some 5 units higher if the FAQ score is 6 instead of 0
(P = 0.005 for the interaction).
Based on the regression model shown in Table 2 we
simulated ADAScog scores after 24 months. The simu-
lated sample (mean 22.1, SD 10.5) showed a very similar
distribution to the observed sample after 24 months
(mean 22.4, SD 10.0). Figure 2 shows a quantile-quantile
plot of simulated versus observed data.
An effective AD treatment is expected to attenuate the
increase of the ADAScog total score at month 24 in
treated compared with untreated MCI subjects. We
assume an effect of 0.16 on the square-root scale of
Table 2 Results of the univariate regression model for
the ADAScog total at month 24
Estimate Standard
error
t value P
value
Intercept 3.84232 0.76473 5.02 <0.0001
Gender 0.28474 0.08387 3.39 0.0008
Obesity -0.27526 0.11680 -2.36 0.019
FAQ at baseline 0.07902 0.01787 4.42 <0.0001
MMSE at baseline -0.06994 0.02534 -2.76 0.0062
ADAScog at baseline 0.09250 0.00768 12.04 <0.0001
NP-Batt at baseline -0.50529 0.08820 -5.73 <0.0001
FAQ × NP-Batt at
baseline
0.03762 0.01341 2.81 0.0054
R2 = 0.6344, standard deviation (residuals) = 0.6692. ADAScog, Alzheimer
Disease Assessment Scale - cognitive subscale; FAQ = Functional Assessment
Questionnaire; MMSE, Mini-Mental State Examination; NP-Batt, Neuro-
Psychological Battery.
Figure 1 Interaction of the Functional Assessment
Questionnaire with the Neuro-Psychological Battery. Interaction
of the Functional Assessment Questionnaire (FAQ) with the Neuro-
Psychological Battery (NP-Batt) in a univariate model for the
Alzheimer Disease Assessment Scale - cognitive subscale (ADAScog)
total score. Lines are shown for quartiles of the FAQ. BL, baseline;
mod., modified.
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ADAScog, corresponding to an improvement of 1 point
at an ADAScog score of 10, or of 2.5 points at an ADAS-
cog score of 60. The analytically derived power with
sample sizes of 286 per group and based on the estimated
SD of the residuals (0.669) in each group is 82%.
Multivariate analysis
The multivariate model is set up with the NP-Batt score
as the outcome. Note that higher NP-Batt scores indi-
cate better performance. Model selection follows the
proposal of Verbeke and Molenberghs [18]. The starting
model is saturated with all fixed main effects, with all
fixed interactions with time and with random intercepts
and random slopes. This model is significantly better
(P < 0.0001, likelihood ratio test) than the model that
drops random slopes. The model hence allows for indi-
vidual regression lines with varying intercepts and slopes
for each patient. Backward stepwise elimination of the
fixed interactions with time and the fixed main effects,
as well as inclusion of other pairwise interactions, is
based on Wald tests. The resulting final model is dis-
played in Tables 3 and 4. NP-Batt at baseline is the
strongest main effect (t = 32.3, P < 0.0001) with a coeffi-
cient of 0.97, which is close to 1.
Obese individuals have a flatter slope of the NP-Batt
score over time than normal weighted individuals (inter-
action P = 0.006). Higher ADAScog baseline scores
increase the slope (graph not shown; interaction P <
0.0001). The number of E4 alleles also increases this
slope (interaction P = 0.0002). We display the effect of
the number of E4 alleles with time in Figure 3, the plot
of this interaction showing a moderate decrease of per-
formance in MCI subjects without an E4 allele and a
steeper decrease in subjects with one or even two E4
alleles.
Fivefold cross-validation confirmed the stability of this
model. The mean prediction error is 0.2176, which is
very close to the corresponding quantity computed from
the residuals (0.2175). The distribution of simulated
NP-Batt values for visits at 6, 12, 18 and 24 months,
based on the demographic and baseline values of
the 375 MCI patients in the ADNI database, was very
similar to the observed data (Table 5).
NP-Batt scores of patients without an E4 allele
decreased with an average slope of -0.094. We hypothe-
size that an effective treatment for secondary prevention
of dementia due to AD might improve this slope by
0.02 to an average slope of -0.074 per visit. Simulating
treatment data with this (alternative) hypothesis and
comparing them with the observed ADNI data as pla-
cebo control achieves a power of about 80% (1,000
simulations).
Supplementary analysis including cerebrospinal fluid
biomarkers
The same model selection strategy as above is used for
the analysis of NP-Batt with the additional covariate
Ab42/T-tau in the cerebrospinal fluid [19]. Random
slopes are again included in the model. The resulting
final model after elimination of most interactions and
some fixed effects is displayed in Tables 6 and 7. NP-
Batt is still the most significant predictor (t = 22.9, P <
0.0001) with a regression coefficient of 1.00. Higher
values of Ab42/T-tau lead to flatter slopes of NP-Batt
scores over time. This interaction is displayed in Figure
4 for Ab42/T-tau values of 1, 1.6 and 3; that is, close to
the quartiles and median value of this covariate. The
interaction of time with ADAScog baseline scores is
somewhat stronger than in the previous analysis (P =
0.0001).
Fivefold cross-validation again confirmed the stability
of the model including Ab42/T-tau. The mean prediction
error coincides with the residual standard deviation -
both are 0.2187, close to the prediction error achieved
from the full sample.
Discussion
The main goal of the current study is to develop mathe-
matical models of typical disease trajectories of AD,
from its presymptomatic to symptomatic stages - that is,
to develop algorithms for use to quantitatively compare
patients undergoing experimental treatment for second-
ary prevention of dementia due to AD with their own
Figure 2 Simulated versus observed Alzheimer Disease
Assessment Scale - cognitive subscale data. Quantile-quantile
plot of simulated versus observed Alzheimer Disease Assessment
Scale - cognitive subscale total scores at month 24.
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anticipated untreated disease course. We used the data
for 397 MCI subjects from the ADNI database as avail-
able in October 2009. The examples presented here con-
cern a univariate (endpoint-related) approach - that is,
an algorithm that predicts the MCI subject group’s per-
formance scores on the ADAScog 24 months after their
baseline examination - and a multivariate (trajectory-
related) approach - that is, an algorithm that forecasts
the decline of performance during 36 months, from
baseline to the last examination after 3 years - on the
composite score of a neuropsychological battery as
described previously (NP-Batt) [15]. Both outcomes, a
cognitive performance score after 24 months and the
trajectory of cognitive change over 36 months, could be
of use in studies with experimental drugs for secondary
prevention of dementia due to AD. A total of 11 demo-
graphic, neuropsychological and biological measures
established at baseline, plus their interactions, were
included as potential predictors in the univariate and
multivariate analyses.
In the univariate model, the strongest predictors of the
ADAScog scores as measured after 24 months were the
ADAScog scores established at baseline. Other signifi-
cant predictors were (in decreasing order of importance)
the composite scores on the NP-Batt, the MMSE scores,
gender and obesity. There was also a significant interac-
tion of the FAQ with the relationship between the NP-
Batt at baseline and the ADAScog scores at 24 months,
suggesting that higher scores on the FAQ (indicating
some functional restriction at baseline) mainly affected
24 months ADAScog scores of MCI subjects with nor-
mal NP-Batt scores at baseline, but not those with lower
baseline performance.
In the multivariate analysis, the strongest predictors of
the NP-Batt trajectory over 36 months were the NP-Batt
scores established at baseline. Other significant, albeit
weaker, predictors are age, the FAQ scores at baseline
and obesity. Of particular interest is the interaction
Table 3 Fixed effects of the mixed model for the Neuro-Psychological Battery
Fixed effects Value Standard error Degrees of freedom t value P value
Intercept 0.92879 0.22683 1,065 4.095 < 0.0001
BMI-2 (category 25 to 30 kg/m2) -0.06911 0.03812 366 -1.813 0.0706
BMI-3 (category >30 kg/m2) -0.04498 0.05337 366 -0.843 0.3999
Visit number 0.01241 0.02184 1,065 0.568 0.5701
Apolipoprotein E4 0.03383 0.02608 366 1.298 0.1953
Age -0.00887 0.00292 366 -3.040 0.0025
FAQ at baseline -0.11273 0.03835 366 -2.939 0.0035
ADAScog at baseline -0.00299 0.00339 366 -0.882 0.3782
NP-Batt at baseline 0.97529 0.03019 366 32.303 <0.0001
(BMI-2) × Visit number 0.02130 0.01366 1,065 1.559 0.1192
(BMI-3) × Visit number 0.05513 0.02003 1,065 2.752 0.0060
Visit number × apolipoprotein E -0.03558 0.00932 1,065 -3.818 0.0001
Visit number × ADAScog -0.00557 0.00104 1,065 -5.374 <0.0001
Age × FAQ 0.00140 0.00051 366 2.723 0.0068
Standard deviation (residuals) = 0.2175. ADAScog, Alzheimer Disease Assessment Scale - cognitive subscale; BMI, body mass index; FAQ, Functional Assessment
Questionnaire; NP-Batt, Neuro-Psychological Battery.
Table 4 Random effects of the mixed model for the
Neuro-Psychological Battery
Random effects Lower limit Value Upper limit
SD(intercept) 0.1424 0.1856 0.2419
SD(slope) 0.0537 0.0677 0.0852
Cor(intercept; slope) -0.2694 0.6544 0.9510
Within-group SD 0.2377 0.2500 0.2629
Standard deviation (SD) and correlation coefficient (Cor) with 95% confidence
intervals.
Figure 3 Interaction of apolipoprotein E4 with the Neuro-
Psychological Battery. Interaction of the number of apolipoprotein
E4 (APO E4) alleles with time in the multivariate model for the
Neuro-Psychological Battery (NP-Batt).
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between the number of apolipoprotein E4 alleles and
time (Figure 3), indicating that the negative impact of
this genetic marker upon cognitive performance was not
significant at baseline but developed over time.
Taken one by one, none of these findings is novel. For
the baseline cognitive measures (ADAScog, MMSE, NP-
Batt) predicting cognitive performance after 24 months
as well as the trajectory of cognitive decline over
36 months, numerous studies show that cognitive per-
formance established at some point in time (memory
function and other cognitive domains) is a strong pre-
dictor of subsequent cognitive decline and of dementia.
This was found, at different levels of performance, for
older subjects who were cognitively healthy at baseline
[20,21], for MCI subjects [22] and for AD patients
[6,23]. The concept of cognitive reserve [24,25] captures
these observations in a more general hypothetical
construct.
The effect of gender was significant in the univariate
approach, but not in the multivariate model. While it is
known from epidemiological studies that AD occurs
more frequently in aged women than in men [26], this
general finding does not explain the difference in the
two models.
Obesity was found to have a protective effect against
cognitive decline in both the univariate model and the
multivariate model. Cronk and colleagues, who also
worked with the ADNI database, have already reported
a favorable impact of higher body mass index baseline
values on the development of MMSE, ADAScog and
NP-Batt scores as early as 1 year after baseline [15].
Other authors also found a protective effect of obesity
upon cognitive performance in persons of older age
[27,28]. Although overweight in middle age was
identified as a risk factor for dementia several decades
later [29,30], this relationship appears to be reversed in
persons beyond 70 years of age (the obesity paradox
[28]). To what extent this paradox and the apparent
protective effect of obesity are due to an underlying
selection factor - for example, higher mortality in over-
weight people lacking a hypothetical protective factor
that also supports cognitive maintenance - cannot be
deducted from the current data.
There was a significant interaction between the FAQ
scores and the NP-Batt scores as predictors of the per-
formance on the ADAScog at 24 months. FAQ scores at
baseline were a significant determinant of cognitive
decline in the multivariate analysis when NP-Batt scores
were still normal (that is, z = 0). As mentioned earlier,
the ADNI MCI sample cannot be considered a pure
selection of MCI subjects since some subjects had
restrictions in activities of daily life and instrumental
activities of daily life, as indicated by baseline FAQ
scores >0 (Table 1), and 60% of the subjects were taking
anti-AD drugs (cholinesterase inhibitors and/or meman-
tine) at some point in the study. With regard to
impaired activities of daily life/instrumental activities of
daily life in some subjects, it is of interest that the base-
line FAQ scores turned out to be a significant and, at
least in the multivariate model, independent predictor of
cognitive decline over the ensuing 36 months. Accord-
ing to Pérès and colleagues, some decline in instrumen-
tal activities of daily life is seen in aged subjects as early
as 10 years before a clinical diagnosis of dementia is
made, and may thus constitute a very early marker of
dementia [31]. Dickerson and colleagues found that, in
mildly impaired aged individuals who did not meet strict
MCI criteria as implemented in clinical trials, the degree
Table 5 Descriptive statistics of observed and simulated NP-Batt scores for MCI at months 6, 12, 18 and 24
Minimum First quartile Median Mean Third quartile Maximum Standard deviation
Observed -3.95 -1.50 -0.97 -1.01 -0.47 1.74 0.83
Simulated -4.12 -1.59 -1.00 -1.04 -0.45 1.85 0.85
MCI, mild cognitive impairment; NP-Batt, Neuro-Psychological Battery.
Table 6 Fixed effects of covariates including Ab42/T-tau in the mixed model for NP-Batt (189 patients)
Fixed effects Value Standard error Degrees of freedom t value P value
Intercept 0.19832 0.09375 564 2.115 0.0348
Visit number -0.07163 0.03346 564 -2.141 0.0327
Ab42/T-tau 0.00328 0.01535 184 0.213 0.8312
FAQ at baseline -0.01015 0.00508 184 -1.999 0.0472
ADAScog at baseline 0.00058 0.00463 184 0.125 0.9007
NP-Batt at baseline 0.99973 0.04373 184 22.861 <0.0001
Visit number × (Ab42/T-tau) 0.02229 0.00548 564 4.065 0.0001
Visit number × ADAScog -0.00398 0.00146 564 -2.719 0.0067
Ab42, b-amyloid1-42; ADAScog, Alzheimer Disease Assessment Scale - cognitive subscale; FAQ, Functional Assessment Questionnaire; NP-Batt, Neuro-Psychological
Battery; T-tau, total tau protein.
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of cognitive impairment in daily life and performance on
neuropsychological testing impacted the likelihood of an
AD diagnosis within 5 years [32].
As for the possible effect of anti-AD medication, sepa-
rate analyses for MCI subjects with and without use of
cholinesterase inhibitors and/or memantine at any time
provided very similar predictive models. Although the
patients taking any of these drugs at some time showed
somewhat inferior cognitive performance at baseline -
that is, higher average ADAScog scores and lower scores
on the NP-Batt than subjects not taking any of these
drugs - the major predictors for the ADAScog scores
after 24 months and the trajectory of the NP-Batt over
36 months were the same for both subgroups (data not
shown).
While the number of apolipoprotein E4 alleles was not
a significant predictor of the ADAScog scores at
24 months in the univariate analysis, this genetic risk
factor of AD showed a significant interaction with time
and, consequently, a strong impact upon the trajectory
of the NP-Batt scores in the longitudinal analysis (Figure
3). Interestingly, the number of apolipoprotein E4 alleles
did no longer significantly affect cognitive performance
when the Ab42/T-tau quotient was introduced as a
potential predictor; note, however, that the analysis
including the cerebrospinal fluid markers was performed
with a sample only one-half as large as that for the
other calculations. The Ab42/T-tau quotient is a known
early marker of AD [19,33] and was recently reported to
be a predictor of functional decline in the ADNI MCI
sample [34]. Ab42 and subsequently tau in the cere-
brospinal fluid are considered early markers in the AD
pathological cascade [35].
In summary, although none of the individually signifi-
cant predictors identified in our models was unexpected,
the specific and weighted combination of predictors is
novel in the models presented: the univariate approach
predicted cognitive performance (ADAScog scores)
2 years after baseline, and the multivariate approach
forecasted the decline of cognitive performance - as
measured by means of the NP-Batt - over 36 months.
The univariate model for the square root of ADAScog
explains 63% of the variance, and the prediction error of
a single outcome in cross-validation is 0.67. This is
obviously not a precise estimate for single values, as the
95% interval for an estimate of ADAScog score of 20
would range roughly from 10 to 34 for an individual
patient. In the application of this model to clinical stu-
dies, however, the relevant measure will be the mean of,
say, 200 outcomes. The standard error of this mean
would be 0.047 on the square-root scale, and the 95%
confidence interval for a mean of 20 on the original
scale would be as narrow as 19.2 to 20.8. In the multi-
variate model for NP-Batt, which has a standard normal
distribution in a healthy population, the standard devia-
tion of the conditional residuals is 0.2175. Taking the
between-patient variability into account, the standard
deviation of residuals in the population is between 0.32
and 0.51, depending on the time of observation (0 to
36 months). For a sample of 200 subjects these standard
deviations are reduced to 0.023 and 0.035, respectively.
Estimated means from such samples appear to be suffi-
ciently precise for group comparisons in clinical trials.
An important point to be addressed in future analyses
concerns the possibility of generalizing our models to
new, independent datasets and, eventually, their applica-
tion in clinical trials of experimental drugs intended for
secondary prevention of dementia due to AD. As a first
step in this direction, the simulation model for the
NP-Batt as derived from the ADNI MCI subjects was
challenged by applying it to the AD patient sample of
the ADNI dataset. NP-Batt data for visits at 6, 12 and
24 months were simulated (there are no data from
AD patients at 18 months). A comparison of the scores
from the observed and the simulated data is shown
in Table 8 and indicates that the observed and the
Table 7 Random effects of the mixed model for NP-Batt
including Ab42/T-tau as covariate (189 patients)
Lower limit Value Upper limit
SD(intercept) 0.1236 0.1816 0.2669
SD(slope) 0.0506 0.0698 0.0962
Cor(intercept, slope) -0.5034 0.5598 0.9487
Within-group SD 0.2342 0.2512 0.2693
Standard deviation (SD) and correlation coefficient (Cor) with 95% confidence
intervals. Ab42, b-amyloid1-42; NP-Batt, Neuro-Psychological Battery; T-tau, total
tau protein.
Figure 4 Interaction of amyloid b42/total tau protein with
time. Interaction of amyloid b42 (Ab42)/total tau protein (T-tau)
with time in the multivariate model for the Neuro-Psychological
Battery (NP-Batt) (189 patients).
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model-based simulated values of the ADNI AD patient
sample were indeed very similar. This is a preliminary
indication that the mathematical model established from
MCI data is also usable for datasets from patients with
dementia; that is, over a wide range of presymptomatic
and symptomatic AD patients. We are currently
testing our models with MCI datasets from other,
ADNI-independent projects, which contained partly
different assessment criteria. The results of these tests
will be reported in due time.
Assuming that our models are supported by analyses
of further independent datasets, what would principally
argue against their use in trials with experimental
compounds aimed at secondary prevention of dementia
due to AD? Evidently, the 50-year tradition of placebo-
controlled study designs in clinical neuropsychopharma-
cology argues against a new approach like the one
suggested here - although several limitations of the
conventional designs have repeatedly been pointed out
[4,7,8].
To illustrate one particularly important limitation of
RPCTs and its consequences, let us for a moment
assume the perspective of an older person who has just
learned that he or she shows the characteristics of pre-
symptomatic AD or MCI, implying that he or she is
likely to become demented within a few years, and who
is offered participation in a long-term phase 3 RPCT
with a promising experimental disease-course altering
drug. Would one not expect that this individual would
be uncertain as to how he or she should decide: agree
to participate in a placebo-controlled - that is, a Russian
roulette type of trial - or reject participation and hope
for a better alternative?
In recent years, clinical investigators - notably in the
United States - have reported increasing difficulties
recruiting patients into AD clinical trials [36]. One can-
not rule out that some of these difficulties are due to
patients’ unwillingness to enter trials that entail a high
risk for participants of being treated with placebo for
months or even years. Thus, apart from the ethical issue
of exposing high-risk individuals to admittedly ineffective
treatment (placebo), one should also consider that only a
self-selected fraction of all trial candidates will eventually
enter RPCTs, a fact that seriously jeopardizes the external
validity of such trials. In spite of these concerns, current
regulatory guidelines [37] and specialized task forces
[38,39] keep recommending or even demand RPCTs as
proof of efficacy for drugs intended for use in AD,
including compounds aimed at secondary prevention of
dementia due to AD that require very long studies to
prove efficacy. This insistence is surprising, given that
placebo-controlled designs were originally developed for
clinical studies of analgesics, antidepressants and anxioly-
tics - that is, for trials in mostly self-limiting, unstable
and partly subjective central nervous system indications
that differ in important aspects from slowly developing,
irreversible, degenerative disorders such as AD.
If supported by further evidence, where in the clinical
development process of a new compound aimed at sec-
ondary prevention of dementia due to AD could be the
place for the proposed PGSA? No doubt some of the
earlier (phase 1 and phase 2) trials, which are often per-
formed on healthy subjects and subsequently on AD
patients at different levels of deterioration, do require
placebo control, notably in order to detect and charac-
terize any relevant safety issue of the new compound.
As these earlier studies last only a few months for each
patient, and since little is known early in development
about a new drug’s potentially useful effect in man,
there is no ethical concern to use placebo at this stage.
Once the proof-of-principle and placebo-controlled
safety studies are completed, however, and presumably
effective and safe doses of the novel drug need to be
tested for long-term efficacy in the target population -
that is, in subjects in presymptomatic stages of AD -
then a placebo-free approach such as the PGSA should
be seriously considered. In addition to its ethical and
scientific merits, it also has the potential to save
patients, time and money. The next years will show
whether the AD research community [3,7,40,41] and
drug regulatory bodies are ready and willing to de-
emphasize a traditional study paradigm that has serious
shortcomings, and are willing to consider a design that
has the potential both to benefit the patients and facili-
tate anti-AD drug development.
Conclusions
First predictive univariate (endpoint-related) and multi-
variate (trajectory related) models based on anamnestic,
clinical, biological and neuropsychological data from the
ADNI database show high correspondence of predicted
and real observed values. Corroboration of these models
Table 8 Descriptive statistics of observed and simulated NP-Batt scores for Alzheimer’s disease patients at months 6,
12 and 24
Minimum First quartile Median Mean Third quartile Maximum Standard deviation
Observed -4.48 -2.66 -1.95 -2.05 -1.40 -0.14 0.87
Simulated -4.85 -2.65 -2.00 -2.08 -1.45 0.10 0.89
Simulation based on the model for mild cognitive impairment individuals. NP-Batt, Neuro-Psychological Battery.
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with data from other studies is ongoing. It is hoped that
the PGSA, which comprises comparisons between real,
observed data of patients on experimental treatment
with their own, model-based forecasted trajectories, will
be considered for late phase 2 or phase 3 long-term
trials with drugs intended for secondary prevention of
dementia due to AD.
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